Acute coronary syndrome: how to reduce the residual inflammatory risk?
Inflammatory mediators play an important role in the pathogenesis of acute coronary syndrome (ACS). The results of experimental and randomized clinical trials on the role of various inflammation inhibitors in the treatment of coronary artery disease (CAD), in particular CANTOS and COLCOT, mark a new...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2020-03-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3720 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689684524924928 |
|---|---|
| author | V. I. Shalnev |
| author_facet | V. I. Shalnev |
| author_sort | V. I. Shalnev |
| collection | DOAJ |
| description | Inflammatory mediators play an important role in the pathogenesis of acute coronary syndrome (ACS). The results of experimental and randomized clinical trials on the role of various inflammation inhibitors in the treatment of coronary artery disease (CAD), in particular CANTOS and COLCOT, mark a new stage that can significantly change the clinical course and outcomes of the disease. We analyze our own experience in studying this problem. There are much prospects for the use of immunomodulatory and anti-inflammatory drugs reducing the residual inflammatory risk, but additional studies are needed to determine their role in the treatment of CAD. |
| format | Article |
| id | doaj-art-9aecd69f35f04a0fa1c0be0d31f4ad5c |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2020-03-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-9aecd69f35f04a0fa1c0be0d31f4ad5c2025-08-20T03:21:32Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202020-03-0125210.15829/1560-4071-2020-2-37202854Acute coronary syndrome: how to reduce the residual inflammatory risk?V. I. Shalnev0I. I. Mechnikov North-West State Medical UniversityInflammatory mediators play an important role in the pathogenesis of acute coronary syndrome (ACS). The results of experimental and randomized clinical trials on the role of various inflammation inhibitors in the treatment of coronary artery disease (CAD), in particular CANTOS and COLCOT, mark a new stage that can significantly change the clinical course and outcomes of the disease. We analyze our own experience in studying this problem. There are much prospects for the use of immunomodulatory and anti-inflammatory drugs reducing the residual inflammatory risk, but additional studies are needed to determine their role in the treatment of CAD.https://russjcardiol.elpub.ru/jour/article/view/3720acute coronary syndromeatherothrombosisinflammationstatinsimmunomodulators |
| spellingShingle | V. I. Shalnev Acute coronary syndrome: how to reduce the residual inflammatory risk? Российский кардиологический журнал acute coronary syndrome atherothrombosis inflammation statins immunomodulators |
| title | Acute coronary syndrome: how to reduce the residual inflammatory risk? |
| title_full | Acute coronary syndrome: how to reduce the residual inflammatory risk? |
| title_fullStr | Acute coronary syndrome: how to reduce the residual inflammatory risk? |
| title_full_unstemmed | Acute coronary syndrome: how to reduce the residual inflammatory risk? |
| title_short | Acute coronary syndrome: how to reduce the residual inflammatory risk? |
| title_sort | acute coronary syndrome how to reduce the residual inflammatory risk |
| topic | acute coronary syndrome atherothrombosis inflammation statins immunomodulators |
| url | https://russjcardiol.elpub.ru/jour/article/view/3720 |
| work_keys_str_mv | AT vishalnev acutecoronarysyndromehowtoreducetheresidualinflammatoryrisk |